Please use this identifier to cite or link to this item:
Title: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
Author: Gately, L.
Mesia, C.
Sepulveda, J. M.
del Barco, S.
Pineda, E.
Girones, R.
Fuster, J.
Hong, W.
Dumas, M.
Gill, S.
Navarro, L. M.
Herrero, A.
Dowling, A.
de las Penas, R.
Vaz, M. A.
Alonso, M.
Lwin, Z.
Harrup, R.
Peralta, S.
Long, A.
Perez-Segura, P.
Ahern, E.
Garate, C. O.
Wong, M.
Campbell, R.
Cuff, K.
Jennens, R.
Gallego, O.
Underhill, C.
Martinez-Garcia, M.
Covela, M.
Cooper, A.
Brown, Stephen
Rosenthal, M.
Torres, J.
Collins, I. M.
Gibbs, P.
Balana, C.
Issue Date: 2024
Publication Title: Journal of Neuro-Oncology
Volume: 166
Issue: 3
Start Page: 407
End Page: 415
Abstract: Purpose The optimal duration of post-radiation temozolomide in newly diagnosed glioblastoma remains unclear, with no published phase III randomised trials. Standard-of-care stipulates 6 months. However, in routine care, it is often extended to 12 months, despite lacking robust supporting data. Methods GEINO14-01 (Spain) and EX-TEM (Australia) studies enrolled glioblastoma patients without progression at the end of 6 months post-radiation temozolomide. Participants were randomised 1:1 to six additional months of temozolomide or observation. Primary endpoint was 6-month progression free survival from date of randomisation (6mPFS). Secondary endpoints included overall survival (OS) and toxicity. 204 patients were required to detect an improvement in 6mPFS from 50 to 60% (80% power). Neither study recruited sufficient patients. We performed a combined analysis of individual patient data. Results 205 patients were recruited: 159 in GEINO14-01 (2014–2018) and 46 in EX-TEM (2019–2022). Median follow-up was 20.0 and 14.5 months. Baseline characteristics were balanced. There was no significant improvement in 6mPFS (57.2% vs 64.0%, OR0.75, p = 0.4), nor across any subgroups, including MGMT methylated; PFS (HR0.92, p = 0.59, median 7.8 vs 9.7 months); or OS (HR1.03, p = 0.87, median 20.1 vs 19.4 months). During treatment extension, 64% experienced any grade adverse event, mainly fatigue and gastrointestinal (both 54%). Only a minority required treatment changes: 4.5% dose delay, 7.5% dose reduction, 1.5% temozolomide discontinuation. Conclusion For glioblastoma patients, extending post-radiation temozolomide from 6 to 12 months is well tolerated but does not improve 6mPFS. We could not identify any subset that benefitted from extended treatment. Six months should remain standard-of-care.
Internal ID Number: 02545
Health Subject: GLIOBLASTOMA
Type: Journal Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.